Covid-19 triggers research culture in Ayurveda, traditional medicines

Of 203 trials registered with the Clinical Trial Registry, 61.5% are from Ayush disciplines

GN Bureau | September 30, 2020


#Covid-19   #Novel Coronavirus   #healthcare   #Ayush ministry   #Ayurveda   #Yoga  
(Illustration: Ashish Asthana)
(Illustration: Ashish Asthana)

The Covid-19 pandemic has brought the spotlight on the health-promotive and disease-preventive solutions of Ayush (Ayurveda, Yoga, Unani, Siddha, Homeopathy) disciplines. What has not come into the limelight is the emerging nationwide trend in the Ayush disciplines, of taking up evidence-based studies.

A study made a thorough search of the Clinical Trial Registry of India for the registered trials of Covid-19 involving ayurveda intervention from March 1 to June 25, without language restrictions. The number of new trials registered in Ayurveda during this period was seen to be 58, the Ayush ministry said in a release on Wednesday.

News reports in August had revealed that out of the 203 trials registered in Clinical Trial Registry of India (CTRI), 61.5% were from Ayush disciplines. A recent study published in the ‘Journal of Research in Ayurvedic Sciences’ titled “Ayurveda Research Studies on Covid-19 Registered in CTRI: A critical appraisal” throws more light on this growing “research-culture” in Ayush disciplines.

Here is some additional insight into these CTRI registered trials involving Ayurveda and Covid-19. Approximately 70% of the total trials registered were sponsored by the government and various stakeholders of Ayurveda associated with the Ayush ministry. These trials will provide useful information to the researchers which will help them to strategize the next course of action and also help the general public for understanding the contribution of Ayurveda in Covid-19.

Once completed, the results of these promising studies will expectedly be published at the earliest so that it will be useful for the policymakers from the Ayush systems of medicines to strategize effective solutions to benefit public health initiatives. Further, in these challenging times, they will provide information for the global scientific community to know about the outcomes of Ayurveda clinical trials being conducted on Covid-19 in India. They will form potential source of information for further collaborative studies at the national and global levels.

Out of the 58 registered trials, 52 (89.66%) are interventional trials and 6 (10.34%) are observational trials. The majority of the trials included adult participants of both the gender as the target population. A total of 53 (91.38%) trials intend to recruit participants aged 18 years or more, and only 05 (8.62%) trials intended to recruit participants younger than 18 years.

The instant paper, which is authored by researchers of the Central Council for Research in Ayurvedic Sciences, provides detailed information about Ayurveda based Covid-19 clinical trials with respect to administrative information on trial registry number and sponsorship, descriptive information on study type and length of study and study design. Further, it tracks information related to the registration date and actual study start date and information related to recruitment, and all these have been collated, presented, and analysed based on the trails’ information registered between March 1 and June 25 in the CTRI.

With an increasing number of registered trials in this field, the body of knowledge in Ayush disciplines will increasingly reflect more contemporary information. This trend of evidence-based studies in the Ayush sector holds considerable promise for the public health activities in the country, as the studies may lead to cost-effective solutions that could be deployed on a nationwide scale.

Comments

 

Other News

Covid norms relaxed; Mumbai restaurants, shops to remain open longer

After extending timings of shops and restaurants as well as the reopening of cinema halls and theatres under specified SOPs from October 22, in view of the festive cheer, the Maharashtra government has allowed restaurants and eateries to remain open till 12AM and shops and establishments to function till 1

Global Hunger Index data collection flawed: Arvind Panagariya

Rubbishing the recently released Global Hunger Index 2021, wherein India has slipped to 101 position to be placed below Pakistan, Nepal and Bangladesh, Arvind Panagariya, professor of economics at Columbia University and former vice chairman, NITI Aayog, has said that data collection and methodologies used

‘Blue Zones’ concept of healthy living and its relevance in India

A long life span free from diseases and disability, the so-called healthy aging, has been a matter of prime interest to humanity. It is widely held that the life expectancy is a function of interplay between various genetic and environmental factors. There is scientific evidence to support the fact that on

Motilal Nehru too had petitioned for release of his son: Vikram Sampath

Defence minister Rajnath Singh’s statement, that Mahatma Gandhi had asked V.D. Savarkar to file a mercy petition before the British, has ignited a debate. Vikram Sampath, a historian and author of a recent biography of Savarkar, says two weeks after Jawaharlal Nehru was lodged in Nabha jail, his

Gati Shakti: The National Master Plan

The launch of the Gati Shakti master plan will be a booster dose for India growth story. The plan, as the name indicates, will ensure Gati, i.e., speed and Shakti, i.e., empowerment to the ₹1 trillion national infrastructure pipeline. The plan will break inter-ministerial silos. For examp

Centre misusing probe agencies for political gains: Pawar

Hitting back at the central government in a strongly worded attack, Nationalist Congress Party (NCP) chief Sharad Pawar has said Bhartiya Janata Party is misusing central investigative agencies for political benefits. “Central agencies including ED, CBI and NCB are being used for polit

Visionary Talk with Dr Arvind Panagariya, Professor, Columbia University & Former VC, NITI Aayog



Archives

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter